01 /Two different worlds
Some peptides are sold as research compounds for laboratory use only. Others are approved as prescription medicines by the FDA or analogous foreign regulators. A handful sit in both worlds simultaneously. Understanding the distinction is fundamental to reading the Apothify library and to making informed research decisions.
The Apothify library lists peptides in both categories but only sells the research compounds. Prescription medicines are represented as encyclopedia entries with no cart pathway.
02 /Research only peptides
A research only peptide is one that has not been approved by the FDA as a drug, biologic, supplement, food, cosmetic, or medical device. It is synthesized by manufacturers, distributed by research peptide suppliers, and sold to research customers with documentation that the product is for laboratory use only.
Most peptides in the Apothify library fall into this category: BPC-157, TB-500, Ipamorelin, CJC 1295 no DAC, Carnosine, the cosmetic peptide family, the Khavinson bioregulator series, and the majority of other entries. The product is real chemistry, the research literature is real, but the regulatory pathway for human use has not been completed.
03 /Prescription medicines
A prescription medicine is a peptide (or peptide analog) that has completed the FDA approval pathway and is sold through pharmacies with a clinician prescription. The list of approved peptide drugs is short but includes several compounds with broad public visibility.
Examples in the Apothify library that are also prescription medicines in regulated markets: Semaglutide (Ozempic, Wegovy), Tirzepatide (Mounjaro, Zepbound), Liraglutide (Victoza, Saxenda), Tesamorelin (Egrifta), Thymosin Alpha-1 (Zadaxin, thymalfasin in many countries), and Bremelanotide (Vyleesi).
When the same compound exists in both research and prescription channels, Apothify classifies it as ELEVATED (encyclopedia only) regardless of any commercial availability through research peptide suppliers. The regulatory exposure is the controlling consideration.
04 /Why the distinction matters
For researchers, the distinction matters because the regulatory pathway determines what data exists. A prescription medicine has been through clinical trials, has dose response data in humans, has known adverse event profiles, and has labeling that documents specific approved indications. A research only peptide typically has none of this.
For commerce, the distinction matters because selling a prescription medicine without a prescription is unlawful in most jurisdictions. Apothify does not do it.
For protocol design, the distinction matters because the available knowledge base is different. Research only peptides have published literature in animal models and cellular research with limited or no human data. Prescription medicines have full clinical trial datasets.
05 /How Apothify classifies peptides
Every peptide in the Apothify library carries a regulatory status of SAFE or ELEVATED.
SAFE means the peptide is offered as a research product. It has a cart pathway, a price, and a product SKU. It has passed the Apothify internal compliance review (no FDA action history, no 503A category 2 listing, no PCAC review in progress, no positioning as a prescription drug).
ELEVATED means the peptide is presented as an encyclopedia entry only. There is no cart, no checkout, and no price. The entry exists for library completeness. The reason is typically regulatory: the compound is a prescription medicine, has been flagged by the FDA, or sits in a category where compliance review is ongoing.
06 /The grey zone
Some peptides do not cleanly fit either category. Examples include compounds that are prescription medicines in some countries but not others, compounds that have moved through advanced clinical research but have not yet been approved, and compounds that have completed approval but for narrow indications outside common public awareness.
Apothify classifies grey zone peptides as ELEVATED by default. The principle is that if there is meaningful regulatory ambiguity, the encyclopedia listing is the appropriate posture; commerce is reserved for cases where the research only status is unambiguous.
07 /What you can and cannot do with a research only peptide
You can study it in laboratory research, including in cell culture, in tissue assays, in animal models with appropriate institutional approval, and in non clinical research contexts.
You cannot administer it to humans for any reason. The research use only framing is not a formality; it is the regulatory boundary that defines the legal status of the product.
You cannot compound it for human use through a pharmacy. Most research only peptides are also on the FDA 503A bulk drug substances list category 2 or have been the subject of compounding pharmacy advisories, which means licensed compounding pharmacies cannot use the bulk substance for clinical preparations.
08 /If you need clinical access
If your research needs a prescription peptide for clinical use, the appropriate channels are: a prescription from a licensed clinician (for approved indications), an Investigational New Drug (IND) application to the FDA (for novel clinical research), or enrollment in an existing clinical trial (for compounds in active development).
Apothify is not a clinical research organization and does not provide any of these pathways. The research only peptides Apothify sells are for laboratory use only.
09 /Reading status on the peptide page
Each peptide page surfaces the regulatory status at the top. SAFE peptides show a green NOTICE and IN STOCK badge with a COA link and a product card. ELEVATED peptides show a yellow NOTICE and Currently unavailable badge with no product card.
The safety and interactions section on every page reiterates the research use only framing. The research notes section may include specific language about regulatory status (the Apothify library lists X for encyclopedia coverage only) for ELEVATED entries.
